PLRX Q3 2024 Earnings — Pliant Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PLRXPliant Therapeutics, Inc.

$85M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$62M

Net Income

-$58M

EPS (Diluted)

$-0.95

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$446M

Total Liabilities

$100M

Stockholders' Equity

$346M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$62M	-$48M	-30.0%
Net Income	-$58M	-$41M	-39.2%